ALMOST 80% OF NEW LC DIAGNOSES
ARE IN NEVERSMOKERS OR
PEOPLE WHO QUIT LONG AGO

 

Final data from Antisoma’s AS1404 lung cancer trial show clear survival benefit

September 27th, 2006

drug trial.jpgCancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces final data from its phase II trial of AS1404 in non-small cell lung cancer. These show a very substantial survival benefit.

 

Posted in Non-Small-Cell, Research, Treatment by Debi

Trackback

 
«
»

Leave a Reply